Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes.
Journal
JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
29
5
2020
medline:
16
6
2021
entrez:
29
5
2020
Statut:
ppublish
Résumé
The 21-gene recurrence score (RS) assay is used to guide breast cancer treatment decisions but can be poorly understood by patients. We examined the effects of a question prompt list (QPL) on knowledge, distress, and decisional conflict related to genomic testing and treatment in early-stage breast cancer. We describe the feasibility and acceptability of the QPL and the impact of the QPL on knowledge, distress, and decisional conflict before and after the receipt of the QPL (MEND 2, N = 65). We also compared distress and decisional conflict between women who received the QPL (MEND 2, N = 65) and a comparable group of women who did not receive the QPL who participated in an earlier observational study within the same clinics (MEND 1, N = 136). MEND 2 participants indicated high acceptability and feasibility using the QPL. Knowledge increased post-QPL ( The findings suggest that the QPL is feasible, acceptable, can improve knowledge and decrease decisional conflict in the large group of women deciding treatment while integrating RS test results.
Identifiants
pubmed: 32463763
doi: 10.1200/JOP.19.00661
pmc: PMC7564130
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1085-e1097Subventions
Organisme : NCI NIH HHS
ID : K99 CA241397
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA201827
Pays : United States
Références
Br J Cancer. 1999 Apr;80(1-2):242-8
pubmed: 10390003
Med Decis Making. 1995 Jan-Mar;15(1):25-30
pubmed: 7898294
Patient Educ Couns. 2017 May;100(5):818-826
pubmed: 28073615
J Cancer Epidemiol. 2012;2012:728290
pubmed: 22899924
Psychooncology. 2015 Mar;24(3):245-52
pubmed: 25082386
N Engl J Med. 2019 Jun 20;380(25):2395-2405
pubmed: 31157962
J Clin Oncol. 2016 Apr 1;34(10):1065-71
pubmed: 26598746
Prev Med. 2004 Apr;38(4):388-402
pubmed: 15020172
J Clin Oncol. 2012 Jun 20;30(18):2218-26
pubmed: 22585699
JAMA Oncol. 2015 Nov;1(8):1098-109
pubmed: 26313372
Eur J Cancer Care (Engl). 2012 Mar;21(2):242-50
pubmed: 22070677
J Clin Oncol. 2019 Aug 1;37(22):1956-1964
pubmed: 31150316
Clin Breast Cancer. 2016 Feb;16(1):59-62
pubmed: 26483315
Psychooncology. 2013 May;22(5):961-77
pubmed: 22585543
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Clin Oncol. 2019 Aug 1;37(22):1965-1977
pubmed: 31206315
Breast Cancer Res Treat. 2013 May;139(1):207-16
pubmed: 23588954
Breast Cancer Res Treat. 2015 May;151(1):149-56
pubmed: 25859924
Breast Cancer Res Treat. 2016 Apr;156(3):549-555
pubmed: 27059031
J Cancer Educ. 2011 Dec;26(4):664-9
pubmed: 21688183
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 26989045
J Natl Compr Canc Netw. 2015 Oct;13(10):1216-24
pubmed: 26483061
BMC Med Inform Decis Mak. 2014 Aug 20;14:73
pubmed: 25142035
Ann Oncol. 1994 Mar;5(3):199-204
pubmed: 8186168
Br J Cancer. 2001 Nov 2;85(9):1273-9
pubmed: 11720460
Psychooncology. 2011 Jan;20(1):28-35
pubmed: 20200857
Cancer. 2008 Jul 15;113(2):225-37
pubmed: 18484592
Breast Cancer Res Treat. 2012 Jun;133(2):553-61
pubmed: 21964579
Ann Surg Oncol. 2015 Nov;22(12):3809-15
pubmed: 25930247
Psychosom Med. 1979 May;41(3):209-18
pubmed: 472086
Breast Cancer Res Treat. 2015 Aug;152(3):611-25
pubmed: 26126971
Patient Educ Couns. 2012 Feb;86(2):252-8
pubmed: 21741195
Ann Surg Oncol. 2016 Oct;23(10):3106-11
pubmed: 27469118
Health Expect. 2015 Oct;18(5):839-49
pubmed: 23432931
Health Psychol. 2008 Mar;27(2):249-57
pubmed: 18377144